Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2024 | $28.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 7/9/2024 | $34.00 → $3.00 | Buy → Hold | Stifel |
| 7/9/2024 | $28.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 7/8/2024 | Buy → Neutral | Guggenheim | |
| 7/8/2024 | $24.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 12/13/2023 | $28.00 | Buy | H.C. Wainwright |
10-Q - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
8-K - HilleVax, Inc. (0001888012) (Filer)
Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously
Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously
H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously
4/A - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
HilleVax's (NYSE:HLVX) short percent of float has risen 14.66% since its last report. The company recently reported that it has 1.55 million shares sold short, which is 20.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.63 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
Leerink Partners analyst David Risinger downgrades HilleVax (NASDAQ:HLVX) from Outperform to Market Perform and lowers the price target from $28 to $2.
Stifel analyst Stephen Willey downgrades HilleVax (NASDAQ:HLVX) from Buy to Hold and lowers the price target from $34 to $3.
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G/A - HilleVax, Inc. (0001888012) (Subject)
SC 13G - HilleVax, Inc. (0001888012) (Subject)
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results As of September 30, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent Business Highlights In Q3 2024, HilleVax announced that the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints and that the company would discontinue further develo
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company's workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates. About HilleVaxHilleVax is a clinical-stage biopharmaceutical company focused on developing a
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date: Tuesday, September 6, 2022Time: 1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator: Eric Joseph, Ph.D.HilleVax Participant: Robert Hershberg, M.D., Ph.D.,
4 - HilleVax, Inc. (0001888012) (Issuer)
4 - HilleVax, Inc. (0001888012) (Issuer)
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy. Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "HilleVax has continued to make excellent progress in our HIL-214 program following completion of enrollment of our NEST-IN1 clinical trial in late April 2023. Due to issues relating solely to the logistical complexity of pr